Contact
Please use this form to send email to PR contact of this press release:
Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)
TO:
Please use this form to send email to PR contact of this press release:
Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)
TO: